Sarepta Therapeutics (FRA:AB3A) 3-Year EBITDA Growth Rate

: 6.40% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Sarepta Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €0.50.

During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sarepta Therapeutics was 43.30% per year. The lowest was -116.30% per year. And the median was -1.00% per year.

Competitive Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics 3-Year EBITDA Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's 3-Year EBITDA Growth Rate falls into.

Sarepta Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sarepta Therapeutics (FRA:AB3A) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sarepta Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (FRA:AB3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SRPT:USA AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (FRA:AB3A) Headlines

No Headlines